Henry Schein
Global healthcare product distributor and services
Chargebacks and Pricing Analyst
More locations: Tours, France
About the job
- Bachelor’s degree in accounting, finance, business administration, economics or relevant professional experience
- Fluent in English
- Professional certifications such as ACCA, CIMA, CPA, or equivalent (completed or in progress) are an advantage
- 1–4 years of professional experience in accounting, financial analysis, pricing, data application, or reporting
- Experience working with data validation, reconciliation, or financial analysis, preferably in a B2B or distribution environment
- Exposure to pricing processes, contract management, or chargeback mechanisms is an advantage
- Experience handling large datasets and performing structured analysis to identify discrepancies or trends
- Familiarity with ERP systems (e.g., JDE,SAP) and/or pricing tools (e.g., Vistex) is a plus
- Experience working in a multinational or EMEA environment is beneficial
- Proven ability to work with cross-functional stakeholders (e.g., Finance, Procurement,Product Management)
- Chargeback Impact Analysis during review periods
- Analyse opportunities,impact on current customer base and opportunities to engage product switching projects to maximise customer experience andenhanceHenry Schein profitability
- Consolidated EMEA claims forkey customers
- Support the creation of a centralised Chargeback database for our EMEA activity,which will in turn help drive the future Vistex Chargeback application
- Conduct timely reviews of contract pricing against cost changes to minimise risk of reduced returns from the fixed price terms
- Impact analysis and opportunities to switch products
- Conducts monthly review of pricing paid by each customer to the terms of their contract to ensure the correct terms are in place
- Ad-hoc reporting for customers,suppliersand projects
- This role is extremely varied; therefore, the job description is notexhaustiveand the role holder willbe requiredtoparticipatein other duties as required by the business.
- Advanced Excel skills (data analysis, reconciliation, reporting)
- Strong analytical thinking and problem-solving capabilities
- Good communications skills, with the ability to collaborate cross-functionally
- Strong sense of business acumen, ownership, and integrity
- Ability to work to deadlines and manage tasks autonomously when required
- A collaborative and reliable team player
- Awareness of the dental/medical industry, products, or suppliers is a plus
About the company
Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Huntington, New York
Founded
1932
Get referred to Henry Schein
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.7% to $3.5 billion, lifting full-year guidance.
- US dental merchandise sales climbed 8.3%, with market-share gains in the United States and Canada.
- Expanded credit facility to $1.25 billion through 2031 funds buybacks, acquisitions, and working capital.
What critics are saying
- July 30, 2026 leadership exits removed COO Ettinger, CSO Mlotek, and supply-chain chief Mullins.
- Dental consumables growth depends on price hikes and DSO demand, not durable procedure acceleration.
- A failed 2026 restructuring would leave HSIC exposed to cheaper distributors and software-first competitors.
What makes Henry Schein unique
- Henry Schein One serves 13,000 customers, and 90% of revenue is recurring.
- Dentrix Ascend AI workflow and MCP platform deepen switching costs for dental practices.
- One Schein unifies distribution, software, and private-label brands across office-based care.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Parental Leave
Short Term Disability
Health Savings Account/Flexible Spending Account
Education Benefits
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 7%Henry Schein has amended and restated its revolving credit agreement, expanding aggregate commitments from $1 billion to $1.25 billion. The facility's termination date has been extended to 19 September 2031. The revised facility, arranged with a syndicate of major international banks, adjusts certain financial definitions and covenants. This provides the healthcare distribution company with greater flexibility in its capital structure. Henry Schein intends to use the enlarged credit facility for working capital and general corporate purposes. These include capital expenditures, share repurchases, refinancing existing debt, and funding potential acquisitions. The agreement includes customary representations, warranties, covenants, and events of default. The company supplies dental, medical, and animal health products to office-based practitioners and healthcare organisations in North America and international markets.
MD Sass Concentrated Value Strategy highlighted Henry Schein as a notable contributor in its second-quarter 2026 investor letter. The healthcare solutions provider saw its shares appreciate 13% during the quarter. The asset management firm believes significant cost reductions combined with accelerating revenue growth should lead to material positive earnings revisions moving into the fourth quarter and 2027. MD Sass met with Henry Schein's new chief executive officer, Fred Lowery, and expects his distribution experience and operational approach to improve efficiencies, margins, and market share. The firm's estimates remain well above consensus over the next several years. Henry Schein closed at $89.52 per share on 28 August 2026, with a market capitalisation of $9.98 billion.
Henry Schein reported second-quarter results that exceeded Wall Street expectations, with revenue of $3.46 billion versus analyst estimates of $3.37 billion and adjusted EPS of $1.27 versus $1.24 expected. The company attributed the performance to accelerating internal sales growth and robust gains in its global dental merchandise segment. CEO Frederick Lowery highlighted success in converting occasional buyers into regular customers and strong market share gains in the US and Canada. The company slightly raised its full-year adjusted EPS guidance to $5.34 at the midpoint. During the earnings call, analysts questioned the sustainability of US dental consumables growth and the timing of value creation benefits. CFO Ronald South indicated most operating income improvements from these initiatives would materialise in the second half of the year.
Henry Schein reported second-quarter sales of $3.5 billion, up 6.7% year-over-year, driven by 4.6% internal local-currency growth and foreign exchange benefits. The healthcare distributor raised its full-year guidance following stronger-than-expected performance. GAAP net income rose to $94 million, or $0.82 per diluted share, from $86 million a year earlier. Non-GAAP earnings reached $1.27 per share, up 15.5% from $1.10 in the prior-year period. Operating margins expanded across all segments. GAAP operating margin increased 27 basis points to 4.94%, whilst non-GAAP operating margin grew 25 basis points to 7.21%. US dental merchandise sales climbed 8.3%, including 6.5% internal growth, with the company reporting market-share gains. Chief Executive Officer Fred Lowery attributed results to operational execution and early benefits from its value-creation programme.
Henry Schein (HSIC), a $9 billion healthcare distribution company, has underperformed the Nasdaq Composite despite recent gains. The stock is up 5.7% over three months, trailing the Nasdaq's 19.2% rise during the same period. Year-to-date, HSIC has gained 4.1% compared to the Nasdaq's 12.6% advance. The Melville, New York-based company, which supplies dental, medical and laboratory products to over one million customers, reported stronger-than-expected first-quarter results on 5 May. Adjusted earnings per share of $1.32 beat analyst estimates of $1.20, whilst revenue of $3.4 billion exceeded forecasts of $3.3 billion. Despite softer medical segment demand from a milder flu season, strength in Home Solutions and technology offerings offset the impact. The company expects full-year adjusted EPS between $5.23 and $5.37.